NCT00988624 - A Study In Healthy Volunteers To Estimate The Pharmacokinetics Of Four Modified-Release Formulations Of Dimebon (Latrepirdine) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions

Alzheimer's DiseaseHuntington Disease

Interventions

DRUG

Dimebon IR Tablet

Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.

DRUG

Dimebon MR1

Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.

DRUG

Dimebon MR2

Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.

DRUG

Dimebon MR3

Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.

DRUG

Dimebon MR4

Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.

Trial Locations (1)

Pfizer Investigational Site, New Haven